美國Forma Therapeutics www.formatherapeutics.com
劍橋馬薩諸塞州的Forma Therapeutics公司多年來一直在探索結(jié)構(gòu)生物學(xué)的藥物發(fā)現(xiàn)途經(jīng)?；诘鞍踪|(zhì)結(jié)構(gòu)的藥物發(fā)現(xiàn)包括兩個(gè)步驟：X射線晶體學(xué)及隨后的計(jì)算機(jī)分析——分析過程借助于Forma公司的CS譜圖專利平臺(tái)，這是一種基于片段大小的計(jì)算機(jī)模擬方法。公司的創(chuàng)建者，首席科學(xué)官Steve Tregay博士詳細(xì)講述了計(jì)算機(jī)模擬技術(shù)的工作原理：通常用含有30~40個(gè)片段的測試集合將蛋白結(jié)構(gòu)表面的測試數(shù)最小化，然后就尋找蛋白質(zhì)表面能夠與片段同源結(jié)合的位點(diǎn)。“我們需要做的就是小心翼翼的繪制出蛋白表面結(jié)合位點(diǎn)的圖譜，并進(jìn)一步鑒定活性位點(diǎn)、變構(gòu)調(diào)節(jié)位點(diǎn)，在更廣闊的蛋白—蛋白結(jié)合的表面發(fā)現(xiàn)關(guān)鍵的互作位點(diǎn)”，Tregay介紹說，“蛋白質(zhì)表面結(jié)構(gòu)的分析及相關(guān)互作位點(diǎn)的鑒別，為藥物靶標(biāo)的篩選、小分子藥物的發(fā)現(xiàn)及先導(dǎo)化合物的優(yōu)化過程提供了很好的途經(jīng)。”
FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.
 
FORMA’s novel approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of a novel generation of small molecule drug candidates with qualified cellular mechanisms of action. FORMA is building a robust pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms.
 

FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.